• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Vegetarian Diet Linked to Reduced Ischemic Stroke Risk in Taiwan
FRIDAY, Feb. 28, 2020 -- In a population from Taiwan, vegetarian diet was associated with a reduced risk for overall, ischemic, and hemorrhagic stroke, according to a study published online Feb. 26 in Neurology. Tina H.T. Chiu, Ph.D., R.D., from Fu...
Source: Drugs.com - Pharma News - February 28, 2020 Category: Pharmaceuticals Source Type: news

Healthful Plant-Based Diet Linked to Lower Total Stroke Risk
WEDNESDAY, March 10, 2021 -- A healthful plant-based diet is associated with a significantly reduced risk for total stroke, according to a study published online March 10 in Neurology. Megu Y. Baden, M.D., Ph.D., from the Harvard T. H. Chan School...
Source: Drugs.com - Pharma News - March 10, 2021 Category: Pharmaceuticals Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Study Reveals Mixed Effects on Health for Vegetarian Diet
FRIDAY, Sept. 6, 2019 -- Vegetarians and fish eaters have a lower risk for ischemic heart disease compared with meat eaters, and vegetarians have a higher risk for stroke, according to a study published online Sept. 4 in The BMJ. Tammy Y.N. Tong,...
Source: Drugs.com - Pharma News - September 6, 2019 Category: Pharmaceuticals Source Type: news

Diets High in Inflammatory Potential Linked to Cardiovascular Disease
TUESDAY, Nov. 3, 2020 -- Dietary patterns with higher inflammatory potential are associated with an increased risk for cardiovascular disease (CVD), coronary heart disease (CHD), and stroke, according to a study published in the Nov. 10 issue of the...
Source: Drugs.com - Pharma News - November 3, 2020 Category: Pharmaceuticals Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news